Hybridan

Our USP is that we are profitable from our corporate retained clients. We do not need to be constantly fundraising for companies, IPO or otherwise, even when it might not be the optimal time to do so which can lead to a “float and forget” mentality, completely ignoring aftermarket support for clients.

Hybridan solves this problem – spending our time with corporates on “non-deal activity.”

  • Consistently putting you in front of investors when you don’t need money in a bid to support aftermarket activity.
  • Regular research to ensure your news flow underpins our investment thesis to a targeted pool of institutional investors.
  • Adopting an agnostic approach to our corporate finance advice to ensure capital is raised in a manner that suits your business – private, public, debt or equity.

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

We communicate the investment cases of our clients to the market through equity research and frequent non-deal investor road shows. We provide market-driven corporate finance advice to our clients to help deliver shareholder value.

We focus on finding new investors who can buy shares in the market and not just in placings.

Hybridan Small Cap Feast - 21 November 2024

* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None What’s baking in the oven? Reverse Takeover: 18 November 2024: Greatland Gold (GGP.L) has entered into an agreement with certain subsidiaries of Newmont...

Hybridan Small Cap Feast - 20 November 2024

* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: Woodside Energy Group Ltd (WDS.L) What’s baking in the oven? ITF announced:*** Potential** Initial Public Offerings: Reverse Takeover: 18 November 2024: Grea...

Hybridan Small Cap Feast - 19 November 2024

* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: Heiq (HEIQ.L) has delisted from the Main Market of the London Stock Exchange. What’s baking in the oven? ITF announced:*** Potential** Initial Public Offerin...

Hybridan Small Cap Feast - 18 November 2024

Status of this Note and Disclaimer This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The i...

Hybridan Friday Takeaway - 15 November 2024

Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication APTA Novel Binders SBDS On Target WPHO Chasing Wind Aptamer Group 0.275p £5.3m (APTA.L) Source: Alpha Terminal Aptamer is a life science Company developing custom affinity binders through its proprietary Optimer platform which enables new approaches in therapeutics, diagnostics, and research applications. Aptamers, affinity reagents, have short single-stranded DNA or RNA, which ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch